Revenue
2012
2013
2015
2016
2017
2018
2019
2020
2022
2023
2024
2025
Phio Pharmaceuticals Corp. (PHIO)
Price$1.08Cached quote
Net income
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | $0 | $21,000 | $138,000 | $15,000 | $19,000 | $34,000 | — | $399,000 | $97,000 | — | — | — | — | — | — | — | — | — |
| Research & development | $4.6M | $3.6M | $6.3M | $7.0M | $8.9M | $3.7M | $4.3M | $4.3M | $5.4M | $5.4M | $6.9M | $5.7M | $17.7M | $3.7M | $6.2M | — | — | — | — | — | — | — | — |
| Operating expenses | $9.2M | $7.4M | $10.8M | $11.5M | $13.5M | $8.8M | $9.0M | $7.5M | $14.1M | $9.0M | $10.3M | $8.9M | $21.3M | $13.1M | — | — | — | — | — | — | — | — | — |
| Operating income | −$9.2M | −$7.4M | −$10.8M | −$11.5M | −$13.5M | −$8.8M | −$9.0M | −$7.4M | −$14.1M | −$9.0M | −$10.2M | −$8.8M | −$20.9M | −$13.0M | −$12.8M | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −42,795.24% | −5,336.23% | −93,746.67% | −47,447.37% | −30,108.82% | — | −5,250.38% | −13,376.29% | — | — | — | — | — | — | — | — | — |
| EBITDA | −$9.2M | −$7.4M | −$10.8M | −$11.4M | −$13.4M | −$8.7M | −$8.9M | −$7.3M | −$14.0M | −$9.0M | −$10.2M | −$8.7M | −$20.9M | −$12.8M | −$12.6M | — | — | — | — | — | — | — | — |
| EBITDA margin | — | — | — | — | — | — | −42,476.19% | −5,277.54% | −93,280.00% | −47,168.42% | −29,882.35% | — | −5,225.56% | −13,224.74% | — | — | — | — | — | — | — | — | — |
| Net income | −$8.7M | −$7.2M | −$10.8M | −$11.5M | −$13.3M | −$8.8M | −$8.9M | −$7.4M | −$12.5M | −$9.0M | −$10.2M | −$8.8M | −$20.9M | −$12.9M | −$2.5M | −$12.0M | −$18.4M | −$14.4M | −$11.0M | −$2.4M | −$2.2M | −$3.3M | −$89,000 |
| Net profit margin | — | — | — | — | — | — | −42,419.05% | −5,333.33% | −83,013.33% | −47,336.84% | −30,067.65% | — | −5,244.36% | −13,278.35% | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$1.45 | -$9,080.00 | -$46.76 | -$90.90 | -$111.87 | -$207.36 | -$2,087.64 | -$6,205.68 | -$32,788.47 | -$97,474.43 | -$124,738,752.61 | -$469,255,307.45 | -$1,710,702,892.97 | -$3,338,246,617.53 | -$151,198,488,015.12 | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$1.45 | -$9,080.00 | -$46.76 | -$90.90 | -$111.87 | -$207.36 | -$2,087.64 | -$6,205.68 | -$32,788.47 | -$97,474.43 | -$124,738,752.61 | -$469,255,307.45 | -$1,710,702,892.97 | -$3,338,246,617.53 | -$151,198,488,015.12 | — | — | — | — | — | — | — | — |
Owners
Reported shareholders
≈3.63%of listed shares
Bitterman Robert J421.42K shares · Jun 26, 2026
View holders
| Holder | % owned |
|---|---|
Bitterman Robert J | ≈3.63%421.42K shares |
JANE STREET GROUP, LLC | 1.01%117.76K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.99%114.57K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.81%94.26K shares |
Carson Lisa Cabott | ≈0.81%94K shares |
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 0.43%50K shares |
Cetera Investment Advisers | 0.41%47.5K shares |
CITADEL ADVISORS LLC | 0.41%47.15K shares |
BRADFORD PATRICIA A | ≈0.39%45.65K shares |
Ferrara Robert L | ≈0.33%38.77K shares |
VANGUARD FIDUCIARY TRUST CO | 0.33%38.17K shares |
Deming David H | ≈0.33%37.8K shares |
Lockshin Curtis | ≈0.30%35.16K shares |
Freeman Jonathan E | ≈0.28%32.66K shares |
NORTHERN TRUST CORP | 0.24%27.77K shares |
TWO SIGMA INVESTMENTS, LP | 0.19%21.5K shares |
XTX Topco Ltd | 0.16%18.48K shares |
HRT FINANCIAL LP | 0.11%13.18K shares |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.10%12K shares |
CITIGROUP INC | 0.10%11.61K shares |
Percentages use 11.62M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 | Bitterman Robert JChairman, Pres. & CEO | BuyCommon Stock, $.0001 par value | 10.0K | $0.99 | $9.9K | 421.4K |
| Dec 31, 2025Form 4 | Bitterman Robert JChairman, Pres. & CEO | BuyCommon Stock, $.0001 par value | 5.0K | $1.03 | $5.2K | 291.4K |
| Dec 23, 2025Form 4 | Bitterman Robert JChairman, Pres. & CEO | BuyCommon Stock, $.0001 par value | 5.0K | $1.02 | $5.1K | 286.4K |
| Nov 21, 2025Form 4 | Bitterman Robert JChairman, Pres. & CEO | BuyCommon Stock, $.0001 par value | 5.0K | $1.14 | $5.7K | 281.4K |
| Nov 18, 2025Form 4 | Bitterman Robert JChairman, Pres. & CEO | BuyCommon Stock, $.0001 par value | 5.0K | $1.27 | $6.3K | 276.4K |